Andere Kunden interessierten sich auch für
![Is patient education program for people with diabetes mellitus cost-effective?]( "Is patient education program for people with diabetes mellitus cost-effective?")
Is patient education program for people with diabetes mellitus cost-effective?58,99 €![Salvaging Diabetic Foot: Cost Effective Methods for Rural Hospitals]( "Salvaging Diabetic Foot: Cost Effective Methods for Rural Hospitals")
Salvaging Diabetic Foot: Cost Effective Methods for Rural Hospitals32,99 €![Microballon loaded with Ondansetron for effective management of Emesis]( "Microballon loaded with Ondansetron for effective management of Emesis")
Microballon loaded with Ondansetron for effective management of Emesis29,99 €![Nanomedicine:A new effective drug for the Treatment of Health Diseases]( "Nanomedicine:A new effective drug for the Treatment of Health Diseases")
Nanomedicine:A new effective drug for the Treatment of Health Diseases24,99 €![Seroprevalence of HBV/HCV-HIV Co-infections and outcome follow up of HAART in HIV Patients]( "Seroprevalence of HBV/HCV-HIV Co-infections and outcome follow up of HAART in HIV Patients")
Seroprevalence of HBV/HCV-HIV Co-infections and outcome follow up of HAART in HIV Patients27,99 €![Kostengünstige Biomarker für die Behandlung von HIV-Erkrankungen]( "Kostengünstige Biomarker für die Behandlung von HIV-Erkrankungen")
Kostengünstige Biomarker für die Behandlung von HIV-Erkrankungen39,90 €![Biomarcatori efficaci dal punto di vista dei costi nella gestione della malattia da HIV]( "Biomarcatori efficaci dal punto di vista dei costi nella gestione della malattia da HIV")
Biomarcatori efficaci dal punto di vista dei costi nella gestione della malattia da HIV26,99 €
The disease burden of human immunodeficiency virus (HIV) is substantially more prevalent among residents of the sub-Saharan Africa and Asia. The availability and affordability of highly active antiretroviral therapy (HAART) have significantly reduced the mortality among HIV-1 infected population, increase their life expectancy and quality of life. However, the poor financial conditions and lack of costly infrastructure in the developing countries hinder regular monitoring of HIV-1 RNA (viral load) and CD4+ T-lymphocyte cell count (TCD4+ cell count). Under these circumstances, there is an increasing need for alternate biomarkers for monitoring the progression of the disease and patient management. Albumin, hemoglobin (Hb), dehydroepiandrosterone sulfate (DHEA-S), red blood cell (RBC) count, erythrocyte sedimentation rate (ESR), plasma highly-sensitive C-reactive protein (hs-CRP), hematocrit (Hct), total lymphocyte count (TLC) are some of the alternate biomarkers with proven utility in the assessment of disease progression.